Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib long-term extension study in rheumatoid arthritis
NL-OMON47671Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2014
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in rheumatoid arthritis (RA) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Treatment-emergent adverse events, Adverse events of special interest and 6 more. Started Feb 2014; status: active, not recruiting.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON47671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47671.